​​​​​​​PsA Treatment Options Expand - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

​​​​​​​PsA Treatment Options Expand

Phase 3 POETYK trial results support FDA approval of deucravacitinib for adults with active PsA.

  • By

  • Kathryn Wighton

  • March 9, 2026

  • 3 min

Share

  • 1

    Deucravacitinib (Sotyktu) is the first TYK2 inhibitor approved for adults with active psoriatic arthritis by the FDA.

  • 2

    The drug demonstrated improved disease activity outcomes in two phase 3 trials compared to placebo.

  • 3

    In the POETYK PsA-1 trial, 54% of patients on deucravacitinib achieved ACR20 response versus 34% on placebo.

  • 4

    The safety profile of deucravacitinib was consistent with previous studies, with common adverse reactions including upper respiratory infections.

  • 5

    Deucravacitinib selectively inhibits TYK2 signaling, affecting interleukin-23, interleukin-12, and type 1 interferon pathways.

Original Source(s)

​​​​​​​PsA Treatment Options Expand

  • by Kathryn Wighton

  • March 9, 2026

Related Content

FDA Approves New Oral Option for Plaque Psoriasis

Phase 3 data showed high skin clearance rates and adverse event rates similar to placebo through week 16 with once-daily icotrokinra.

Psoriatic Arthritis Linked to Rare Vocal Issue

Bilateral vocal cord immobility linked to cricoarytenoid joint fixation highlights diagnostic consideration for unexplained airway symptoms.

Does TYK2/JAK1 Show Potential in Inflammatory Diseases?

Investigational inhibitor was not associated with treatment-related serious adverse events and produced biomarker changes consistent with pathway inhibition in healthy volunteers.